Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;50(4):1251-1259.
doi: 10.1002/jmri.26692. Epub 2019 Feb 21.

Susceptibility-weighted imaging in malignant melanoma brain metastasis

Daniel Schwarz  1   2 , Thomas Niederle  1 , Philipp Münch  1   3 , Thomas Hielscher  4 , Jessica C Hassel  5 , Heinz-Peter Schlemmer  2 , Michael Platten  3   6 , Frank Winkler  7   8 , Wolfgang Wick  7   8 , Sabine Heiland  1 , Stefan Delorme  2 , Martin Bendszus  1 , Philipp Bäumer  2 , Michael O Breckwoldt  1   3
Affiliations

Susceptibility-weighted imaging in malignant melanoma brain metastasis

Daniel Schwarz et al. J Magn Reson Imaging. 2019 Oct.

Abstract

Background: The value of cerebral susceptibility-weighted imaging (SWI) in malignant melanoma (MM) patients remains controversial and the effect of melanin on SWI is not well understood.

Purpose: To systematically analyze the spectrum of intracerebral findings in MM brain metastases (BM) on SWI and to determine the diagnostic value of SWI.

Study type: Retrospective.

Population/subjects: In all, 100 patients with melanoma BM (69 having received radiotherapy [RT] and 31 RT-naïve) and a control group of 100 melanoma patients without BM were included. For detailed analysis of signal characteristics, 175 metastases were studied.

Field strength/sequence: Gradient echo SWI sequence at 1.5, 3.0, and 9.4 T.

Assessment: Signal characteristics from melanotic and amelanotic BMs on SWI with a focus on blooming artifacts were analyzed, as well as the presence and longitudinal dynamics of isolated SWI blooming artifacts in patients with and without BM.

Statistical tests: Chi-squared and Student's t-test were used for contingency table measures and group data of signal and clinical characteristics, respectively.

Results: Melanotic and amelanotic metastases did not show significant differences of SWI blooming artifacts (38% vs. 43%, P = 0.61). Most metastases without an initial SWI artifact developed a signal dropout during follow-up (80%; 65/81). Isolated SWI artifacts were detected more frequently in patients with BM (20 vs. 9, P = 0.03), of which the majority were found in patients who had received RT (17 vs. 3, P = 0.08). None of these isolated SWI blooming artifacts turned into overt metastases over time (median follow-up: 8.5 months). Similar findings persisted as remnants of successfully treated metastases (88%; 7/8).

Data conclusion: We conclude that SWI provides little additional diagnostic benefit over standard T1 -weighted imaging, as melanin content alone does not cause diagnostically relevant SWI blooming. Signal transition of SWI may rather indicate secondary phenomena like microbleeding and/or metal scavenging. Our results suggest that isolated SWI artifacts do not constitute vital tumor tissue but represent unspecific microbleedings, RT-related parenchymal changes or posttherapeutic remnants of former metastatic lesions.

Level of evidence: 3 Technical Efficacy Stage: 5 J. Magn. Reson. Imaging 2019;50:1251-1259.

Keywords: brain metastasis; magnetic resonance imaging; melanoma; susceptibility weighted imaging.

PubMed Disclaimer

References

    1. Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S. Evolving treatment options for melanoma brain metastases. Lancet Oncol 2015;16:e486-497.
    1. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014;383:816-827.
    1. Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM. Advances in therapy for melanoma brain metastases. Clin Dermatol 2013;31:264-281.
    1. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-133.
    1. Cohen JV, Tawbi H, Margolin KA, et al. Melanoma central nervous system metastases: Current approaches, challenges, and opportunities. Pigment Cell Melanoma Res 2016;29:627-642.

Publication types